Cytyc and TriPath rush for share of UK LBC (liquid-based cytology) pie
This article was originally published in Clinica
Executive Summary
Cytyc's monopoly of the US liquid-based cytology (LBC) market is likely to be mirrored in the UK as the country's conversion to LBC for cervical cancer screening begins to gather momentum, analysts predict.